Koo, 

Yes, this is a new sub-study of the ODYSSEY anti-PCSK9 alirocumab antibody trial focusing on the MACE events in high risk diabetic patients who have experienced an ACS event within past 12 months. Dr. Kausik Ray (chair of BETonMACE CSC) presented it yesterday at American Diabetes Association meeting in Orlando (FYI Resverlogix is presenting poster there too). The take home message is that alirocumab elicits robust LDL lowering and about a 15% relative risk reduction in MACE in both diabetic and non-diabetic patients. The absolute risk reduction elicited by alirocumab in diabetic patients is about double that observed in non-diabetic patients, which is not surprising given that diabetic patients have a much higher residual risk relative to non-diabetic patients. That latter point about the absolute risk reduction is the big headline. However, the relative risk reduction elicited by alirocumab in diabetics is on par with the about 15% elicited by SGLT2 inhibitors, GLP1R agonists, and anti-IL1B therapies in recent diabetes CVOT trials. So this new sub study is nice, but not surprising.

BearDownAZ